|
gptkbp:instanceOf
|
gptkb:drug
immunosuppressant
mTOR inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2009
|
|
gptkbp:ATCCode
|
L01EG02
|
|
gptkbp:bioavailability
|
~30%
|
|
gptkbp:brand
|
gptkb:Afinitor
gptkb:Zortress
|
|
gptkbp:CASNumber
|
gptkb:159351-69-6
|
|
gptkbp:chemicalFormula
|
C53H83NO14
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to everolimus
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
~30 hours
|
|
gptkbp:form
|
gptkb:tablet
tablet for oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
everolimus
|
|
gptkbp:interactsWith
|
gptkb:milk
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:KEGGID
|
D08914
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits mTORC1
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
958.2 g/mol
|
|
gptkbp:origin
|
derivative of sirolimus
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB01590
CHEMBL121
6442177
|
|
gptkbp:relatedTo
|
gptkb:sirolimus
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fatigue
infections
rash
hyperglycemia
hyperlipidemia
mouth ulcers
|
|
gptkbp:storage
|
below 25°C
|
|
gptkbp:UNII
|
9HW64Q8G6G
|
|
gptkbp:usedFor
|
gptkb:tuberous_sclerosis_complex
gptkb:cancer
gptkb:subependymal_giant_cell_astrocytoma
renal cell carcinoma
neuroendocrine tumors
organ transplant rejection prevention
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
gptkb:mTOR_pathway
gptkb:Afinitor
|
|
gptkbp:bfsLayer
|
5
|